Unlike other brands that release their ads days or weeks ahead of the Big Game, Novartis is waiting to unveil its commercial ...
AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...
Earnings reflect R&D investments in 2024 including the acquisition of Kate Therapeutics, Mariana Oncology, IFM Due, MorphoSys AG, Calypso Biotech BV, and SanReno Therapeutics. Additionally, as the ...
The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...
Q4 2024 Earnings Call Transcript January 31, 2025 Novartis AG beats earnings expectations. Reported EPS is $1.98, ...
Novartis’ results show the firm humming along nicely in 2024, with sales driven by continued strong performance from its ...
Good morning and good afternoon, and welcome to the Novartis Q4 2024 results release conference call and live webcast.
Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +12% (cc1, +11% USD) with core operating income1 up +22% (cc, +19% USD) Sales growth driven by continued strong performance ...
Net sales grew +12% (cc 1, +11% USD) with core operating income 1 up +22% (cc, +19% USD) Sales growth driven by continued st ...
Leiden, the Netherlands, January 21, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Board of Directors has nominated Fabrice ...
Novartis is the latest drugmaker to sue the government for allegedly rejecting its proposed model to distribute federal drug discounts.
As the company faces criticism for its decision last year to not renew insurance policies for 72,000 property owners in California, State Farm has nixed plans to run a commercial during this year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback